Skip to main content
SpringerLink
Log in

Individual Variation in First-Pass Metabolism

  • Review Article
  • Clinical Pharmacokinetic Concepts
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Individual variation in pharmacokinetics has long been recognised. This variability is extremely pronounced in drugs that undergo extensive first-pass metabolism. Drug concentrations obtained from individuals given the same dose could range several-fold, even in young healthy volunteers.

In addition to the liver, which is the major organ for drug and xenobiotic metabolism, the gut and the lung can contribute significantly to variability in first-pass metabolism. Unfortunately, the contributions of the latter 2 organs are difficult to quantify because conventional in vivo methods for quantifying first-pass metabolism are not sufficiently specific. Drugs that are mainly eliminated by phase II metabolism (e.g. estrogens and progestogens, morphine, etc.) undergo significant first-pass gut metabolism. This is because the gut is rich in conjugating enzymes. The role of the lung in first-pass metabolism is not clear, although it is quite avid in binding basic drugs such as lidocaine (lignocaine), propranolol, etc.

Factors such as age, gender, disease states, enzyme induction and inhibition, genetic polymorphism and food effects have been implicated in causing variability in pharmacokinetics of drugs that undergo extensive first-pass metabolism. Of various factors considered, age and gender make the least evident contributions, whereas genetic polymorphism, enzymatic changes due to induction or inhibition, and the effects of food are major contributors to the variability in first-pass metabolism. These factors can easily cause several-fold variations. Polymorphic disposition of imipramine and propafenone, an increase in verapamil first-pass metabolism by rifampicin (rifampin), and the effects of food on propranolol, metoprolol and propafenone, are typical examples.

Unfortunately, the contributions of these factors towards variability are unpredictable and tend to be drug-dependent. A change in steady-state clearance of a drug can sometimes be exacerbated when first-pass metabolism and systemic clearance of a drug are simultaneously altered. Therefore, an understanding of the source of variability is the key to the optimisation of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abernethy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. Journal of the American Geriatric Society 32: 705–708, 1984

    CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. Journal of Pharmacology and Experimental Therapeutics 232: 183–188, 1985

    PubMed  CAS  Google Scholar 

  • Ablad B, Borg KO, Johnsson G, Regårdh C-G, Solvell L. Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man. Life Sciences 14: 693–704, 1974

    Article  PubMed  CAS  Google Scholar 

  • Alam, AN, Saha JR, Dobkin JF, Lindenbaum J. Interethnic variation in the metabolic inactivation of digoxin by the gut flora. Gastroenterology 95: 117–123, 1988

    PubMed  CAS  Google Scholar 

  • Aldercrueutiz H, Pulkkinen MO, Hamalainen EK, Korpela JT. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones. Journal of Steroid Biochemistry 20: 217–2291, 1984

    Article  Google Scholar 

  • Alván G, Borgå O, Lind M, Palmer L, Siwers B, et al. First-pass hydroxylation of nortriptyline: concentration of parent drug and major metabolites in plasma. European Journal of Clinical Pharmacology 11: 219–224, 1977a

    Article  PubMed  Google Scholar 

  • Alván G, Lind M, Mellstrom B, von Bahr C. Importance of ‘first-pass elimination’ for individual differences in steady-state concentrations of the adrenergic β-antagonist alprenolol. Journal of Pharmacokinetics and Biopharmaceutics 5: 193–205, 1977b

    PubMed  Google Scholar 

  • Alván G, Piafsky K, Lind M, von Bahr C. Effect of pentobarbital on the disposition of alprenolol. Clinical Pharmacology and Therapeutics 22: 316–321, 1977c

    PubMed  Google Scholar 

  • Alván G. Interindividual differences in the disposition of drugs metabolised in the body. Clinical Pharmacokinetics 3: 155–175, 1978

    Article  PubMed  Google Scholar 

  • Axelson JE, Chan GLY, Kirsten EB, Aason WD, Lanman RC, et al. Food increases the bioavailability of propafenone. British Journal of Clinical Pharmacology 23: 735–741, 1987

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Breckenridge AM, Crawford FE, Orme ML’E, Rowe PH, et al. First-pass effect of norethindrone in rabbits and rats. Journal of Pharmacology and Experimental Therapeutics 207: 555–565, 1978

    PubMed  CAS  Google Scholar 

  • Back DJ, Bates M, Breckenridge AM, Ellis A, Hall JM, et al. The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestrel by human jejunal mucosa. British Journal of Clinical Pharmacology 11: 275–278, 1981a

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Breckenridge AM, Maciver M, Orme ML’E, Purba H, et al. Interaction of ethinyloestradiol with ascorbic acid in man. British Medical Journal 282: 1516, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Breckenridge AM, Maciver M, Orme ML’E, Purba HS, et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. British Journal of Clinical Pharmacology 13: 325–330, 1982

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Breckenridge MC, Crawford FE, Challiner M, Orme ML, et al. The effect of antibiotics on the enterohepatic circulation of ethinyl-estradiol and norethisterone in the rat. Journal of Steroid Biochemistry 9: 527–531, 1978

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Rogers SM. First-pass metabolism by gastrointestinal muscosa. Alimentary Pharmacology and Therapeutics 1: 339–357, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bai SA, Wilson MJ, Walle UK, Walle T. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. Journal of Pharmacology and Experimental Therapeutics 227: 360–364, 1983

    PubMed  CAS  Google Scholar 

  • Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268–269, 1991

    Article  PubMed  CAS  Google Scholar 

  • Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. Age and Ageing 18: 258–262, 1989

    Article  PubMed  CAS  Google Scholar 

  • Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenorst RL, et al. The effect of enzyme induction on verapamil pharmacokinetics: verapamil-rifampicin interaction. Drug Intelligence and Clinical Pharmacy 21: 11A, 1987

    Google Scholar 

  • Baron J, Voigt JM. Localization, distribution, and induction of xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung. Pharmacology and Therapeutics 47: 419–445, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bass L, Keiding S, Winkler K, Tygstrup N. Enzymatic elimination of substrates flowing through the intact liver. Journal of Theoretical Biology 61: 393–409, 1976

    Article  PubMed  CAS  Google Scholar 

  • Bateman DN, Kahn C, Davies DS. The pharmacokinetics of metoclopramide in man with observations in the dog. British Journal of Clinical Pharmacology 9: 371–377, 1980

    Article  PubMed  CAS  Google Scholar 

  • Belpaire FM, Bogaert MG, Rosseneu M. Binding of β-adrenoceptor blocking drugs to human serum albumin, to α 1 -acid glycoprotein and to human serum. European Journal of Clinical Pharmacology 22: 253–256, 1982

    Article  PubMed  CAS  Google Scholar 

  • Bendayan R, Pieper JA, Stewart RB, Caranasos GJ. Influence of age on serum protein binding of propranolol. European Journal of Clinical Pharmacology 26: 251–254, 1984

    Article  PubMed  CAS  Google Scholar 

  • Bennett PN, Aarons LJ, Bending MR, Steiner JA, Rowland M, et al. Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. Journal of Pharmacokinetics and Biopharmaceutics 10: 265–281, 1982

    PubMed  CAS  Google Scholar 

  • Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti G, et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients undergoing regular dialysis treatment. Clinical Pharmacokinetics 1: 373–384, 1976

    Article  PubMed  CAS  Google Scholar 

  • Blanchard J. Protein binding of caffeine in young and elderly males. Journal of Pharmaceutical Sciences 71: 1415–1418, 1982

    Article  PubMed  CAS  Google Scholar 

  • Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clinical Pharmacokinetics 4: 423–432, 1979

    Article  PubMed  CAS  Google Scholar 

  • Blychert E, Edgar B, Elmfeldt D, Hedner T. A population study of the pharmacokinetics of felodipine. British Journal of Clinical Pharmacology 31: 15–24, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bondesson U, Lindström L. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psycho-pharmacology 95: 472–475, 1988

    CAS  Google Scholar 

  • Borm BJA, Frankhuijzen-Sierevogel A, Noordhoek J. Kinetics of in vitro O-demethylation of phenacetin and 7-ethoxycoumarin by rat intestinal mucosal cells and microsomes: the effect of induction with 3-methylcholanthrene and inhibition with α-naphthoflavone. Biochemical Pharmacology 32: 1573–1580, 1983

    Article  PubMed  CAS  Google Scholar 

  • Boyd E. Normal variability in weight of the adult human liver and spleen. Archives of Pathology 16: 350–372, 1933

    Google Scholar 

  • Boyes RN, Scott DB, Jebson PJ, Godman MJ, Julian DG, et al. Pharmacokinetics of lidocaine in man. Clinical Pharmacology and Therapeutics 12: 105–116, 1971

    PubMed  CAS  Google Scholar 

  • Breimer DD. Individual variations in drug disposition: clinical implications and methods of investigation. Clinical Pharmacokinetics 8: 371–377, 1983

    Article  PubMed  CAS  Google Scholar 

  • Brewster D, Humphrey MJ, Mcleavy MA. The systemic bioavailability of buprenorphine by various routes of administration. Journal of Pharmacy and Pharmacology 33: 500–506, 1981

    Article  PubMed  CAS  Google Scholar 

  • Brode E, Muller-Peltzer H, Hollman R. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. Methods and Findings in Experimental and Clinical Pharmacology 10: 717–727, 1988

    PubMed  CAS  Google Scholar 

  • Brogden RN, Heel RC, Speight TM, Avery GS. Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163–197, 1977

    Article  PubMed  CAS  Google Scholar 

  • Brösen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clinical Pharmacokinetics 18: 220–239, 1990

    Article  PubMed  Google Scholar 

  • Brösen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics 43: 400–406, 1988

    Article  PubMed  Google Scholar 

  • Brunk SF, Delle M. Morphine metabolism in man. Clinical Pharmacology and Therapeutics 16: 51–57, 1974

    PubMed  CAS  Google Scholar 

  • Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, et al. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. British Journal of Clinical Pharmacology 17: 45S–50S, 1984

    Article  PubMed  Google Scholar 

  • Caldwell J, Marsh MV. Metabolism of drugs by the gastrointestinal tract. In George et al. (Eds) Clinical pharmacology and therapeutics: presystemic drug elimination, pp. 29–42, Butter-worths, London, 1982

    Google Scholar 

  • Calloway NO, Foley CF, Lagerbloom P. Uncertainties in geriatric data II: organ size. Journal of the American Geriatrics Society 13: 20–28, 1965

    PubMed  CAS  Google Scholar 

  • Cammarata RJ, Rodnan GP, Fennell RM. Serum anti-gamma globulin and anti-nuclear factors in the aged. Journal of the American Medical Association 199: 115–118, 1967

    Article  Google Scholar 

  • Campion EW, deLaby LO, Glynn RJ. The effect of age on serum albumin in healthy males: report from the normative aging study. Journal of Gerontology 43: M18–M20, 1988

    PubMed  CAS  Google Scholar 

  • Cappiello M, Franchi M, Giuliani L, Pacifici GM. Distribution of 2-naphthol sulphotransferase and its endogenous substrate adenosine 3′-phosphate 5′-phosphosulphate in human tissues. European Journal of Clinical Pharmacology 37: 317–320, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cappiello M, Giuliani L, Pacifici GM. Distribution of UDP-glucuronosyltransferase and its endogenous substrate undine 5′-diphosphoglucuronic acid in human tissues. European Journal of Clinical Pharmacology 41: 345–350, 1991

    Article  PubMed  CAS  Google Scholar 

  • Cassidy M, Houston JB. In vivo assessment of extrahepatic conjugative metabolism in first-pass effects using the model compound phenol. Journal of Pharmacy and Pharmacology 32: 57–59, 1980

    Article  PubMed  CAS  Google Scholar 

  • Cassidy M, Houston JB. In vivo capacity of hepatic and extra-hepatic enzymes to conjugate phenol. Drug Metabolism and Disposition 12: 619–624, 1984

    PubMed  CAS  Google Scholar 

  • Chow MSS, Lebsack C, Hilleman D. Propafenone: a new antiarrhythmic agent. Clinical Pharmacy 7: 869–877, 1988

    PubMed  CAS  Google Scholar 

  • Christophidis N, Vajda FJE, Lucas I, Drummer LO, Moon WJ, et al. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clinical Pharmacokinetics 3: 330–336, 1978

    Article  Google Scholar 

  • Cleveland CR, Shand DG. Effect of route of administration on the relationship between β-adrenergic blockade and plasma propranolol level. Clinical Pharmacology and Therapeutics 13: 181–185, 1972

    Google Scholar 

  • Colli A, Buccino G, Cocciolo M, Parravicini R, Scaltrini G. Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clinical Pharmacology and Therapeutics 44: 642–649, 1988

    Article  PubMed  CAS  Google Scholar 

  • Collste P, Seideman P, Borg KO, Haglund K, von-Bahr C. Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol. Clinical Pharmacology and Therapeutics 25: 423–427, 1979

    PubMed  CAS  Google Scholar 

  • Conney AH, Pantuck EJ, Kuntzman R, Kappas A, Anderson KE, et al. Nutrition and chemical bio-transformation in man. Clinical Pharmacology and Therapeutics 22: 707–719, 1977

    PubMed  CAS  Google Scholar 

  • Connolly S, Lebsack C, Winkle RA, Harrison DC, Katas RE. Propafenone disposition kinetics in cardiac arrhythmia. Clinical Pharmacology and Therapeutics 36: 163–168, 1984

    Article  PubMed  CAS  Google Scholar 

  • Cooper TB, Kelly RG. GLC analysis of lozapine, amoxapine and their metabolites in serum and urine. Journal of Pharmaceutical Sciences 68: 216–219, 1979

    Article  PubMed  CAS  Google Scholar 

  • Cullum ME, Zile MH. Metabolism of all-trans-retinoic acid and all-trans-retinyl acetate. Demonstration of common physiological metabolites in rat small intestinal mucosa and circulation. Journal of Biological Chemistry 260: 10590–10596, 1985

    PubMed  CAS  Google Scholar 

  • Curry SH, D’Mello A, Mould GP. Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. British Journal of Pharmacology 42: 403–411, 1971

    Article  PubMed  CAS  Google Scholar 

  • Cusack B, O’Malley K, Lavan J, Noel J, Kelly JG. Protein binding and disposition of lignocaine in the elderly. European Journal of Clinical Pharmacology 29: 323–329, 1985

    Article  PubMed  CAS  Google Scholar 

  • Dahl SG. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clinical Pharmacology and Therapeutics 19: 435–422, 1976

    PubMed  CAS  Google Scholar 

  • Dahlstrom BE, Paalzow LK. Pharmacokinetic interpretation of enterohepatic recirculation and first-pass elimination of morphine in the rat. Journal of Pharmacokinetics and Biopharmaceutics 6: 505–519, 1978

    PubMed  CAS  Google Scholar 

  • Dayer P, Leemann T, Marmy A, Rosenthaler J. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behavior of atenolol, bopindolol and metoprolol. European Journal of Clinical Pharmacology 28: 149–153, 1985

    Article  PubMed  CAS  Google Scholar 

  • Dicafaluzy E, Franksson C, Lisboa BP, Martinsen B. Formation of oestrone glucosiduronate by the human intestinal tact. Acta Endocrinologica 40: 537–551, 1962

    Google Scholar 

  • Dicafaluzy E, Franksson C, Martinsen B. Oestragen conjugation by the human intestinal tract. Acta Endocrinologica 38: 59–72, 1961

    Google Scholar 

  • Dobkin JF, Saha JR, Butler VPJR, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 220: 325–327, 1983

    Article  CAS  Google Scholar 

  • Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clinical Pharmacology and Therapeutics 22: 251–258, 1977

    PubMed  CAS  Google Scholar 

  • Drayer DE. Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clinical Pharmacokinetics 1: 426–443, 1976

    Article  PubMed  CAS  Google Scholar 

  • Durnas C, Loi C-M, Cusak BJ. Hepatic drug metabolism and aging. Clinical Pharmacokinetics 19: 359–389, 1990

    Article  PubMed  CAS  Google Scholar 

  • du Souich P, Lery N, Lery L, Varin S, Boucher M, et al. Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules. Biopharmaceutics and Drug Disposition 11: 137–147, 1990

    Article  Google Scholar 

  • Edes TE, Clinton SK, Treux R, Visek WJ. Intestinal and hepatic mixed function oxidase activity in rats fed methionine and cysteine-free diets. Proceedings Society of Experimental Biology Medicine 162: 71–74, 1979

    CAS  Google Scholar 

  • Edwards DJ. Evidence favoring the venous equilibrium model for hepatic clearance of (S)-(−)-propranolol. Journal of Pharmaceutical Sciences 73: 1498–1499, 1984

    Article  PubMed  CAS  Google Scholar 

  • Edwards DJ, Lalka D, Cerra F, Slaughter RL. Alpha-1-acid glycoprotein concentration and protein binding in trauma. Clinical Pharmacology and Therapeutics 32: 62–68, 1982

    Article  Google Scholar 

  • Edwards DJ, Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics of pethidine: 1982. Clinical Pharmacokinetics 7: 421–433, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ehrnebo M, Boreus LO, Lönroth U. Bioavailability and first-pass metabolism of oral pentazocine in man. Clinical Pharmacology and Therapeutics 22: 888–892, 1977

    PubMed  CAS  Google Scholar 

  • Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics 7: 1–22, 1982

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Birkel P, Grube E, Guetgemann U, Somogyi A. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klinische Wochenschrift 58: 919–925, 1980

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labeled verapamil. European Journal of Clinical Pharmacology 19: 133–137, 1981

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology 16: 183–187, 1979

    Article  PubMed  CAS  Google Scholar 

  • Eldere JV, Parmentier G, Robben J, Eyssen H. Influence of an estrone-sulfating intestinal flora on the enterohepatic circulation of estrone-sulfate in rats. Journal of Steroid Biochemistry 26: 235–239, 1987

    Article  PubMed  Google Scholar 

  • Elvin AT, Cole AFD, Pieper JA, Robin SH, Lalka D. Effect of food on lidocaine kinetics: mechanism of food related alteration in high intrinsic clearance drug elimination. Clinical Pharmacology and Therapeutics 30: 455–460, 1981

    Article  PubMed  CAS  Google Scholar 

  • Ervik M. Quantitative determinant of metoprolol in plasma and urine by gas chromatography. Acta Pharmacologica et Toxicologica 36 (Suppl. 5): 136–144, 1975

    PubMed  CAS  Google Scholar 

  • Evans GH, Shand DG. Disposition of propranolol V: drug accumulation and steady-state concentration during chronic oral administration in man. Clinical Pharmacology and Therapeutics 14: 487–493, 1973

    PubMed  CAS  Google Scholar 

  • Evans MA, Triggs EJ, Broe GA, Saines N. Systemic availability of orally administered L-dopa in the elderly Parkinsonian patient. European Journal of Clinical Pharmacology 17: 215–221, 1980

    Article  PubMed  CAS  Google Scholar 

  • Feely J, Nadeau J, Wood AJJ. Effects of feeding on the systemic clearance of indocyanine green and propranolol blood concentrations and plasma binding. British Journal of Clinical Pharmacology 15: 383–385, 1983

    Article  PubMed  CAS  Google Scholar 

  • Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. New England Journal of Medicine 304: 692–695, 1981

    Article  PubMed  CAS  Google Scholar 

  • Findlay JWA, Butz RF, Welch RM. Codeine kinetics as determined by radioimmunoassay. Clinical Pharmacology and Therapeutics 22: 439–446, 1977

    PubMed  CAS  Google Scholar 

  • Fotherby K. Variability of pharmacokinetic parameters for contraceptive steroids. Journal of Steroid and Biochemistry 19: 817–820, 1983

    Article  CAS  Google Scholar 

  • Freedman SB, Richmond DR, Ashley JJ, Kelly DT. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clinical Pharmacology and Therapeutics 30: 644–652, 1981

    Article  PubMed  CAS  Google Scholar 

  • Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs, Part I: pharmacodynamic and pharmacokinetic properties. American Heart Journal 97: 663–670, 1979

    Article  PubMed  CAS  Google Scholar 

  • Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimisation of therapy with β-adrenergic blocking agents. Clinical Pharmacokinetics 20: 311–318, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ganguly J. Absorption of vitamin A. American Journal of Nutrition 22: 923–933, 1969

    CAS  Google Scholar 

  • Garcha F, Imrie PR, Marley E, Thomas DV. [14C]-beta-phenylethylamine, its distribution after administration by various routes to cats, and the effects of monoamine oxidase inhibitors. British Journal of Pharmacology 86: 877–888, 1985

    Article  PubMed  CAS  Google Scholar 

  • George CF. Drug metabolism in the gastrointestinal mucosa. Clinical Pharmacokinetics 6: 259–274, 1981

    Article  PubMed  CAS  Google Scholar 

  • Gerkens JF, Desmond PV, Schenker S, Branch RA. Hepatic and extrahepatic glucuronidation of lorazepam in the dog. Hepatology 1: 329–335, 1981

    Article  PubMed  CAS  Google Scholar 

  • Giacomini KM, Giacomini JC, Gibson TP, Levy G. Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt. Clinical Pharmacology and Therapeutics 28: 417–424, 1980

    Article  PubMed  CAS  Google Scholar 

  • Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G. Pharmacokinetics of d-propoxyphene in anephric patients. Clinical Pharmacology and Therapeutics 21: 103, 1977

    Google Scholar 

  • Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G. Propoxyphene and norpropoxyphene plasma concentrations in anephric patient. Clinical Pharmacology and Therapeutics 27: 665–670, 1980

    Article  PubMed  CAS  Google Scholar 

  • Gillespie MN, Felder TB, Blanford SL, Reinsel CN, Kostenbauder HB. Pulmonary disposition and pharmacodynamics of verapamil. Journal of Cardiovascular Pharmacology 6: 802–807, 1984

    Article  PubMed  CAS  Google Scholar 

  • Gillette JR. Factors affecting drug metabolism. Annals of the New York Academy of Sciences 179: 43–66, 1971

    Article  PubMed  CAS  Google Scholar 

  • Giudicelli JF, Tillement JP. Influence of sex on drug kinetics in man. Clinical Pharmacokinetics 2: 157–166, 1977

    Article  PubMed  CAS  Google Scholar 

  • Goldman P, Koch RL, Yeung TC, Chrystal EJT, Beaulieu Jr BB, et al. Comparing the reduction of nitro-imidazoles in bacteria and mammalian tissues and relating it to biological activity. Biochemical Pharmacology 35: 43–51, 1986

    Article  PubMed  CAS  Google Scholar 

  • Gomoll AW, Byrne JE, Mayol RF. Comparative antiarrhythmic (AA) and local anesthetic actions of encainide (E) and its two major metabolites. Pharmacologist 23: 209, 1981

    Google Scholar 

  • Gorbach SL. Estrogens, breast cancer, and intestinal flora. Revue of Infectious Diseases 6 (Suppl. 1): S85–S90, 1984

    Article  Google Scholar 

  • Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25: 297–312, 1986

    Article  PubMed  CAS  Google Scholar 

  • Gram LF, Overø KF. First-pass metabolism of nortriptyline in man. Clinical Pharmacology and Therapeutics 18: 305–314, 1975

    PubMed  CAS  Google Scholar 

  • Gram LF, Schou J, Way WL, Heltberg J, Bodin NO. d-Propoxyphene kinetics after single oral and intravenous doses in man. Clinical Pharmacology and Therapeutics 26: 473–482, 1979

    PubMed  CAS  Google Scholar 

  • Gram LF, Christiansen J. First-pass metabolism of imipramine in man. Clinical Pharmacology and Therapeutics 17: 555–563, 1975

    PubMed  CAS  Google Scholar 

  • Granerus A, Jagenburg R, Svanborg A. Intestinal decarboxylation of L-dopa in relation to dose requirement in Parkinson’s disease. Naunyn-Schmiedeberg’s Archives of Pharmacology 280: 429–439, 1973

    Article  PubMed  CAS  Google Scholar 

  • Gray MR, Tarn YK. A series-compartment model for hepatic elimination. Drug Metabolism and Disposition 15: 27–31, 1987

    PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Allen MD, Locniskar A, Harmatz JS, Shader RI. Lorazepam kinetics in the elderly. Clinical Pharmacology and Therapeutics 26: 103–113, 1979

    PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, et al. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. Journal of Pharmacology and Experimental Therapeutics 202: 365–378, 1977

    PubMed  CAS  Google Scholar 

  • Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11: 2275–2279, 1990

    Article  PubMed  CAS  Google Scholar 

  • Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P, Schoerlin MP. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatrica Scandinavica (Suppl. 360): 91–93, 1990

    Google Scholar 

  • Guentert TW, Holford NHG, Coates PE, Upton RA, Riegelman S, et al. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. Journal of Pharmacokinetics and Biopharmaceutics 7: 315–330, 1979

    PubMed  CAS  Google Scholar 

  • Haglund K, Seideman P, Collste P, Borg KO, von-Bahr. Influence of pentobarbital on metoprolol plasma levels. Clinical Pharmacology and Therapeutics 26: 326–329, 1979

    PubMed  CAS  Google Scholar 

  • Harris PA, Riegelman S. Influence of the route of administration on the area under the plasma concentration-time curve. Journal of Pharmaceutical Sciences 58: 71–75, 1969

    Article  PubMed  CAS  Google Scholar 

  • Hartvig P, Askmark H, Aquilonius SM, Wiklund L, Lindstrom B. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. European Journal of Clinical Pharmacology 38: 259–263, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hawksworth G, Drasar BS, Hill MJ. Intestinal bacteria and the hydrolysis of glycosidic bonds. Journal of Medicinal Microbiology 4: 451–459, 1971

    Article  CAS  Google Scholar 

  • Hengstmann JH, Hengstmann R, Schwonzen S, Dengler HJ. Dihydroergotamine increases the bioavailability of orally administered etilefrine. European Journal of Clinical Pharmacology 22: 463–467, 1982

    Article  PubMed  CAS  Google Scholar 

  • Herman RJ, McAllister CB, Branch RA, Wilkinson GR. Effects of age on meperidine disposition. Clinical Pharmacology and Therapeutics 37: 19–24, 1985

    Article  PubMed  CAS  Google Scholar 

  • Hermann Ph, Rodger SD, Remones G, Thenot JP, London DR, et al. Pharmacokinetics of diltiazem after intravenous and oral administration. European Journal of Clinical Pharmacology 24: 349–352, 1983

    Article  PubMed  CAS  Google Scholar 

  • Holford NHG, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. British Journal of Clinical Pharmacology 11: 187–195, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH. Investigations on the pharmacokinetics of propafenone in man. Arzneimittel-Forschung 33: 763–770, 1983

    PubMed  CAS  Google Scholar 

  • Homeida, Jackson L, Roberts CJC. Decreased first-pass metabolism of labetalol in chronic liver disease. British Medical Journal 2: 1048–1050, 1978

    Article  PubMed  CAS  Google Scholar 

  • Homeida MMA, Ali HM, Arbab BMO, Harron DWG. Propranolol disposition in patients with hepatosplenic schistosomiasis. British Journal of Clinical Pharmacology 24: 393–396, 1987

    Article  PubMed  CAS  Google Scholar 

  • Huet PM, LeLorier J. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. Clinical Pharmacology and Therapeutics 28: 208–215, 1980

    Article  PubMed  CAS  Google Scholar 

  • Huet PM, LeLorier J, Pomier G, Marleau D. Bioavailability of lidocaine in normal volunteers and cirrhotic patients. Gastroenterology 75: 969, 1978

    Google Scholar 

  • Ilett KF, Davies DS. In vivo studies of gut wall metabolism. In George et al. (Eds) Clinical pharmacology and therapeutics: presystemic drug elimination, pp. 43–65, Butterworths, London, 1982

    Google Scholar 

  • Ilett KF, Tee LBG, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacology and Therapeutics 46: 67–93, 1990

    Article  PubMed  CAS  Google Scholar 

  • Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. Canadian Journal of Physiology and Pharmacology 62: 860–862, 1984

    Article  PubMed  CAS  Google Scholar 

  • Inturrisi CE, Colburn WA, Verebey K, Dayton HE, Woody GE. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clinical Pharmacology and Therapeutics 31: 157–167, 1982

    Article  PubMed  CAS  Google Scholar 

  • Iwamoto K, Klassen CD. First-pass effect of morphine in rats. Journal of Pharmacology and Experimental Therapeutics 200: 236–244, 1977

    PubMed  CAS  Google Scholar 

  • Iwamoto K, Takei M, Watanabe J. Gastrointestinal and hepatic first-pass metabolism of aspirin in rat. Journal of Pharmacy and Pharmacology 34: 176–180, 1981

    Article  Google Scholar 

  • Iwamoto K, Watanabe J, Aoyama Y. High capacity for pulmonary first-pass elimination of propranolol in rats. Journal of Pharmacy and Pharmacology 39: 1049–1051, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Iwamoto K, Watanabe J, Yamada M, Atsumi F, Matsushita T. Effect of age on gastrointestinal and hepatic first-pass effects of levodopa in rats. Journal of Pharmacy and Pharmacology 39: 421–425, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Jaillon P, Gardin ME, Lecocq B, Richard MO, Meignam S, et al. Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. Clinical Pharmacology and Therapeutics 46: 226–233, 1989

    Article  PubMed  CAS  Google Scholar 

  • Jänchen E, Bechtold H, Kasper W, Kersting F, Just H, et al. Lorcainide I: saturable pre-systemic elimination. Clinical Pharmacology and Therapeutics 26: 187–195, 1979

    Google Scholar 

  • Jeffery DJ, Jones KH, Langley PF. The metabolism of talampicillin in rat, dog and man. Xenobiotica 8: 419–427, 1978

    Article  PubMed  CAS  Google Scholar 

  • Jusko WJ. Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 6: 7–39, 1978

    PubMed  CAS  Google Scholar 

  • Kalow W. Genetics of drug transformation. Clinical Biochemistry, 19: 76–82, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kates RE, Keefe DL, Schwartz J, Sandra H, Kirsten EB, et al. Verapamil disposition kinetics in chronic atrial fibrillation. Clinical Pharmacology and Therapeutics 30: 44–51, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kates RE, Keefe DL, Winkle RA. Lorcainide disposition kinetics in arrhythmia patients. Clinical Pharmacology and Therapeutics 33: 28–34, 1983

    Article  PubMed  CAS  Google Scholar 

  • Kato R. Sex-related differences in drug metabolism. Drug Metabolism Reviews 3: 1–32, 1974

    Article  PubMed  CAS  Google Scholar 

  • Keiding S, Andreasen PB. Hepatic clearance measurements and pharmacokinetics. Pharmacology 19: 105–110, 1979

    Article  PubMed  CAS  Google Scholar 

  • Keiding S. Hepatic elimination kinetics: the influence of hepatic blood flow on clearance determinations. Scandinavian Journal of Clinical Laboratory Medicine 36: 113–118, 1976

    Article  CAS  Google Scholar 

  • Kleinbloesem CH, van Brummelen P, van del Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clinical Pharmacology Therapeutics 35: 742–749, 1984

    Article  CAS  Google Scholar 

  • Klippert PJM, Hulshoff A, Mingels MJ, Hofman G, Noordhoek J. Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism. Cancer Research 43: 3160–3164, 1983

    PubMed  CAS  Google Scholar 

  • Koch RL, Goldman P. The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid. Journal of Pharmacology and Experimental Therapeutics 208: 406–410, 1979

    PubMed  CAS  Google Scholar 

  • Koch RL, Chrystal EJT, Beaulieu Jr BB, Goldman P. Acetamide — a metabolite of metronidazole formed by the intestinal flora. Biochemical Pharmadology 29: 3611–3615, 1979

    Article  Google Scholar 

  • Kornhauser DM, Wood AJJ, Vestal RE, Wilkinson GR, Branch RA. Biological determinants of propranolol disposition in man. Clinical Pharmacology and Therapeutics 23: 165–174, 1978

    PubMed  CAS  Google Scholar 

  • Koster AS, Hofman GA, Frankhuijzen-Sierevogel AC, Noordhoek J. Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. Drug Metabolism and Disposition 13: 464–470, 1985

    PubMed  CAS  Google Scholar 

  • Koster AS, Frankhuijzen-Siervogel C, Noordhoek J. Glucuronidation of morphine and six beta 2-sympathomimetics in isolated rat intestinal epithelial cells. Drug Metabolism and Disposition 13: 232–238, 1985

    PubMed  CAS  Google Scholar 

  • Kowey PR, Kirsten EB, Fu CHJ, Mason WD. Interaction between propranolol and propafenone in healthy volunteers. Journal of Clinical Pharmacology 29: 512–517, 1989

    PubMed  CAS  Google Scholar 

  • Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, et al. Effects of aging and liver disease on disposition of lorazepam. Clinical Pharmacology and Therapeutics 24: 411–419, 1978

    PubMed  CAS  Google Scholar 

  • Krause W, Kühne G, Seifert W. Pharmacokinetics of 3H-terguride in elderly volunteers. Arzneimittel-Forschung 41: 373–377, 1991

    PubMed  CAS  Google Scholar 

  • Krebs HA, Sykes WO, Bartley WC. Acetylation and deacetylation of p-amino group of sulfonamide drugs in animal tissues. Biochemical Journal 41: 622–630, 1947

    PubMed  CAS  Google Scholar 

  • Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJJ, Eichelbaum M, et al. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 79: 1068–1076, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology 26: 753–759, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lamboeuf Y, De Saint-Blanquat G, Derache R. Mucosal dehydrogenase-mediated ethanol oxidation in the digestive tract of the rat. Biochemical Pharmacology 30: 542–545, 1981

    Article  PubMed  CAS  Google Scholar 

  • Lamboeuf Y, La Droitte PH, De Saint-Blanquat G. The gastrointestinal metabolism of ethanol in the rat: effect of chronic alcoholic intoxication. Archives Internationales de Pharmacodynamie et de Thérapie 261: 157–169, 1983

    PubMed  CAS  Google Scholar 

  • Larsson M, Landahl S, Lundborg P, Regårdh CG. Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after single dose and two weeks treatment. European Journal of Clinical Pharmacology 27: 217–222, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lee JT, Yee Y-G, Dorian P, Kates RE. Influence of hepatic dysfunction on the pharmacokinetics of propafenone. Journal of Clinical Pharmacology 27: 384–389, 1987

    PubMed  CAS  Google Scholar 

  • Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, et al. Oxidation phenotype — major determinant of metoprolol metabolism and response. New England Journal of Medicine 307: 1558–1560, 1982

    Article  PubMed  CAS  Google Scholar 

  • Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clinical Pharmacology and Therapeutics 34: 732–737, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of β-adrenoeeptor antagonists: clinical pharmacokinetic considerations. Clinical Pharmacokinetics 11: 1–17, 1986

    Article  PubMed  CAS  Google Scholar 

  • Lindenbaum J, Preibisz JJ, Butler Jr VP, Saha JR. Variation in digoxin bioavailability: a continuing problem. Journal of Chronic Diseases 26: 749–754, 1973

    Article  CAS  Google Scholar 

  • Lindenbaum J, Rund DG, Butler Jr JP, Tse-Eng D, Saha JR. Inactivation of digoxin by gut flora: reversal by antibiotic therapy. New England Journal of Medicine 305: 789–794, 1981a

    Article  PubMed  CAS  Google Scholar 

  • Lindenbaum J, Tse-Eng D, Butler Jr VP, Rund DG. Urinary excretion of reduced metabolites of digoxin. American Journal of Medicine 71: 67–74, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Löfström JB, Aim B-E, Bertler Å, Jorfeldt L, Lewis D, et al. Lung uptake of lidocaine. Acta Anaesthesiologica Scandinavica (Suppl. 70): 80–82, 1978

    Google Scholar 

  • Love BL, Moore RG, Thomas J, Chaturvedi S. Pharmacokinetics of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. European Journal of Clinical Pharmacology 20: 135–139, 1981

    Article  PubMed  CAS  Google Scholar 

  • Ludden TM, McNay Jr JL, Shepherd AMM, Lin MS. Clinical pharmacokinetics of hydralazine. Clinical Pharmacokinetics 7: 185–205, 1982

    Article  PubMed  CAS  Google Scholar 

  • Lundahl J, Miniscalco A, Edgar B, Regårdh CG, Eriksson UG, et al. Effects of flavonoids on the oxidative metabolism of felodipine and nifedipine. In Abstracts of the Third North American International Society for Study of Xenobiotics Meeting, San Diego, 1990. pp. 21–25, ISSX, Bethesda, 1990

  • Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586, 1977

    Article  PubMed  CAS  Google Scholar 

  • Mahon WA, Inaba T, Stone RM. Metabolism of flurazepam by the small intestine. Clinical Pharmacology and Therapeutics 22: 228–233, 1977

    PubMed  CAS  Google Scholar 

  • Mantyla R, Allonen H, Kanto J, Kleimola T, Sellman R. Effect of food on the bioavailability of labetalol. British Journal of Clinical Pharmacology 9: 435–437, 1980

    Article  PubMed  CAS  Google Scholar 

  • Mason WD, Winer N. Pharmacokinetics of oxprenolol in normal subjects. Clinical Pharmacology and Therapeutics 20: 401–412, 1976

    PubMed  CAS  Google Scholar 

  • Mather LE, Tucker GT. Systemic availability of orally administered meperidine. Clinical Pharmacology and Therapeutics 20: 535–540, 1976

    PubMed  CAS  Google Scholar 

  • Matsumoto K, Miyazaki H, Fujii T, Yoshida K, Amejima H, et al. Disposition and metabolism of the novel antihypertensive agent alacepril in rats. Arzneimittel-Forschung 36: 40–46, 1986

    PubMed  CAS  Google Scholar 

  • Mayersohn M. Special pharmacokinetic considerations in the elderly. In Evans et al. (Eds) Applied pharmacokinetics — principles of therapeutic drug monitoring, pp. 229–293, Applied Therapeutics, Spokane, 1986

    Google Scholar 

  • McAllister Jr RG, Foster TS, Hamann SR, Richard V. Pharmacokinetics of nifedipine after single intravenous (IV) and oral (PO) doses in normal subjects. Clinical Research 30: 763A, 1982

    Google Scholar 

  • McAllister Jr RG, Kirsten EB. The pharmacology of verapamil: IV. Kinetics and dynamic effects after single intravenous and oral doses. Clinical Pharmacology and Therapeutics 31: 418–426, 1982

    Article  PubMed  CAS  Google Scholar 

  • McLean A, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clinical Pharmacokinetics 21: 42–69, 1991

    Article  PubMed  CAS  Google Scholar 

  • McLean AJ, McNamara PJ, du Souich P, Gibaldi M, Lalka D. Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clinical Pharmacology and Therapeutics 24: 5–10, 1978

    PubMed  CAS  Google Scholar 

  • McLean AJ, Skews H, Bobik A, Dudley FJ. Interaction between oral propranolol and hydralazine. Clinical Pharmacology and Therapeutics 27: 726–732, 1980

    Article  PubMed  CAS  Google Scholar 

  • Meinertz T, Kasper W, Kersting F, Just H, Bechtold H, et al. Lorcainide II: plasma concentration-effect relationship. Clinical Pharmacology and Therapeutics 26: 196–204, 1979

    PubMed  CAS  Google Scholar 

  • Melander A, Berlin-Wahlen A, Bodin N-O, Danielson K, Gustafsson B, et al. Bioavailability of d-propoxyphene, acetylsalicylic acid, and phenazone in a combination tablet (Doleron®): interindividual variation and influence of food intake. Acta Medica Scandinavica 202: 119–124, 1977a

    Article  PubMed  CAS  Google Scholar 

  • Melander A, Danielson K, Scherstén B, Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clinical Pharmacology and Therapeutics 22: 108–112, 1977b

    PubMed  CAS  Google Scholar 

  • Melander A, Danielson K, Hanson A, Rudell B, Schersten B, et al. Enhancement of hydralazine bioavailability by food. Clinical Pharmacology and Therapeutics 22: 104–107, 1977c

    PubMed  CAS  Google Scholar 

  • Melander A, McLean A. Influence of food intake on presystemic clearance of drugs. Clinical Pharmacokinetics 8: 286–296, 1983

    Article  PubMed  CAS  Google Scholar 

  • Mellstrom B, Alván G, Bertilsson L, Potter WZ, Säwe J, et al. Nortriptyline formation after single oral and intramuscular doses of amitriptyline. Clinical Pharmacology and Therapeutics 32: 664–667, 1982

    Article  PubMed  CAS  Google Scholar 

  • Mikus G, Fischer C, Heuer B, Heuer B, Langen C, et al. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. British Journal of Clinical Pharmacology 24: 561–569, 1987

    Article  PubMed  CAS  Google Scholar 

  • Mistry M, Houston JB. Glucuronidation in vitro and in vivo: comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metabolism and Disposition 15: 710–717, 1987

    PubMed  CAS  Google Scholar 

  • Mistry M, Houston JB. Quantitation of extrahepatic metabolism: pulmonary and intestinal conjugation of napthol. Drug Metabolism and Disposition 13: 740–745, 1985

    PubMed  CAS  Google Scholar 

  • Modi MW, Hassett JM, Lalka D. Influence of posture on hepatic perfusion and the presystemic biotransformation of propranolol: simulation of the food effect. Clinical Pharmacology and Therapeutics 44: 268–274, 1988

    Article  PubMed  CAS  Google Scholar 

  • Moore RG, Triggs EJ, Shanks CA, Thomas J. Pharmacokinetics of chlormethiazole in humans. European Journal of Clinical Pharmacology 8: 353–357, 1975

    Article  PubMed  CAS  Google Scholar 

  • Morgan DJ, Smallwood RA. Clinical significance of pharmacokinetic models of hepatic elimination. Clinical Pharmacokinetics 18: 61–67, 1990

    Article  PubMed  CAS  Google Scholar 

  • Naranjo CA, Sellers EM, Khouw V. Unaltered serum propranolol binding by meal induced variations in fatty acids. British Journal of Clinical Pharmacology 13: 575–576, 1982

    PubMed  CAS  Google Scholar 

  • Nation RL, Triggs EJ, Selig M. Lignocaine kinetics in cardiac patients and aged subjects. British Journal of Clinical Pharmacology 4: 439–448, 1977a

    Article  PubMed  CAS  Google Scholar 

  • Nation RL, Vine J, Triggs EJ, Learoyd B. Plasma level of chlormethiazole and two metabolites after oral administration to young and aged human subjects. European Journal of Clinical Pharmacology 12: 137–145, 1977b

    Article  PubMed  CAS  Google Scholar 

  • Neal EA, Meffin PJ, Gregory PB, Blaschke TF. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 77: 96–102, 1979

    PubMed  CAS  Google Scholar 

  • Nies AS, Shand DG, Wilkinson GR. Altered hepatic blood flow and drug disposition. Clinical Pharmacokinetics 1: 135–155, 1976

    Article  PubMed  CAS  Google Scholar 

  • Ochs HR, Greenblatt DJ, Woo E, Franke K, Pfiefer HJ, et al. Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. American Journal of Cardiology 41: 770–777, 1978

    Article  PubMed  CAS  Google Scholar 

  • Orme ML’E, Back DJ, Breckenridge M. Clinical pharmacokinetics of oral contraceptive steroids. Clinical Pharmacokinetics 8: 95–136, 1983

    Article  PubMed  CAS  Google Scholar 

  • Pacifici GM, Temellini A, Giuliani L, Rane A, Thomas H, et al. Cytosolic epoxide hydrolase in humans: development and tissue distribution. Archives in Toxicology 62: 254–257, 1988b

    Article  CAS  Google Scholar 

  • Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, et al. Tissue distribution of drug metabolizing enzymes in humans. Xenobiotica 18: 849–856, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Pang KS, Rowland M. Hepatic clearance of drugs I: theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model; influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmaceutics 5: 625–653, 1977

    PubMed  CAS  Google Scholar 

  • Pantuck EJ, Hsiac KC, Maggio A, Nakamura K, Kuntzman R, et al. Effect of cigarette smoking on phenacetin metabolism. Clinical Pharmacology and Therapeutics 15: 9–17, 1974

    PubMed  CAS  Google Scholar 

  • Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clinical Pharmacology and Therapeutics 25: 88–95, 1979

    PubMed  CAS  Google Scholar 

  • Pelkonen O, Puurunen J. The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochemical Pharmacology 29: 3075–3080, 1980

    Article  PubMed  CAS  Google Scholar 

  • Pentikainen PJ, Neuvonen PJ, Tarpila S, Syvalahti E. Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole. British Medical Journal 2: 861–863, 1978

    Article  PubMed  CAS  Google Scholar 

  • Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. Journal of Pharmacology and Experimental Therapeutics 181: 555–562, 1972

    PubMed  CAS  Google Scholar 

  • Perucca E, Grimaldi R, Gatti G, Caravaggi M, Crema F, et al. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. British Journal of Clinical Pharmacology 18: 37–43, 1984

    Article  PubMed  CAS  Google Scholar 

  • Perucca E, Richens A. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. British Journal of Clinical Pharmacology 7: 21–31, 1979

    Article  Google Scholar 

  • Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou J-P. Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 74: 566–571, 1978

    PubMed  CAS  Google Scholar 

  • Piafsky KM, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha-1-acid glycoprotein. New England Journal of Medicine 229: 1435–1439, 1978

    Article  Google Scholar 

  • Pierce DM, Abrams SML, Franklin RA. Bioavailability and pharmacokinetics in volunteers of the anti-hypertensive agent indoramin and its metabolite 6-hydroxyindoramin. European Journal of Clinical Pharmacology 32: 619–623, 1987

    Article  PubMed  CAS  Google Scholar 

  • Pond SM, Tong T, Benowitz NL, Jacob P. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. Australian and New Zealand Journal of Medicine 10: 515–519, 1980

    Article  PubMed  CAS  Google Scholar 

  • Pond SM, Tong T, Benowitz NL, Jacob P, Rigod J. Presystemic metabolism of meperidine to normeperidine in normal cirrhotic subjects. Clinical Pharmacology and Therapeutics 30: 183–188, 1981

    Article  PubMed  CAS  Google Scholar 

  • Pond SM, Tozer TN. First-pass elimination: basic concepts and clinical consequences. Clinical Pharmacokinetics 9: 1–25, 1984

    Article  PubMed  CAS  Google Scholar 

  • Posadas FA, Juarez FJ, Garcia C. Biotransformation of organic nitrate esters in vitro by human liver, intestine, and blood serum. Drug Metabolism and Disposition 16: 477–481, 1988

    Google Scholar 

  • Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, et al. Active metabolites of imipramine and desipramine in man. Clinical Pharmacology and Therapeutics 31: 393–401, 1982

    Article  PubMed  CAS  Google Scholar 

  • Rahn KH, Moody J, Bohm R, v d Vet A. Reduction of bioavailability of verapamil by rifampicin. New England Journal of Medicine 312: 920–921, 1985

    PubMed  CAS  Google Scholar 

  • Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clinical Pharmacology and Therapeutics 28: 769–778, 1980

    Article  PubMed  CAS  Google Scholar 

  • Regårdh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. The pharmacokinetics of omeprazole in humans — a study of single intravenous and oral doses. Therapeutic Drug Monitoring 12: 163–172, 1990

    Article  PubMed  Google Scholar 

  • Regårdh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clinical Pharmacokinetics 5: 557–569, 1980

    Article  PubMed  Google Scholar 

  • Regårdh CG, Landahl S, Larsson M, Lundberg P, Steen B, et al. Pharmacokinetics of metoprolol and its metabolite α-OH-me-toprolol in healthy, non-smoking, elderly individuals. European Journal of Clinical Pharmacology 24: 221–226, 1983

    Article  PubMed  Google Scholar 

  • Reilly PEB, Winzor DJ. Adverse drug interactions with cimetidine: competitive inhibition of monooxygenase-dependent N-demethylation of morphine. Biochemical Pharmacology 33: 1151–1153, 1984

    Article  PubMed  CAS  Google Scholar 

  • Reimann IW, Klotz U, Frolich J. Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clinical Pharmacology and Therapeutics 32: 749–757, 1982

    Article  PubMed  CAS  Google Scholar 

  • Reimann IW, Klotz U, Siems B, Frolich J. Cimetidine increases steady state plasma levels of propranolol. British Journal of Clinical Pharmacology 12: 785–790, 1981

    Article  PubMed  CAS  Google Scholar 

  • Reiter MJ, Shand DG, Pritchett ELC. Comparison of intravenous and oral verapamil dosing. Clinical Pharmacology and Therapeutics 32: 711–720, 1982

    Article  PubMed  CAS  Google Scholar 

  • Rendic S, Kajfez, Ruf HH. Characterization of cimetidine, ranitidine and related structures’ interaction with cytochrome P-450. Drug Metabolism and Disposition 11: 137–142, 1983

    PubMed  CAS  Google Scholar 

  • Rendic S, Sunjic V, Toso R, Kajfez F, Ruf HH. Interaction of cimetidine with liver microsomes. Xenobiotica 9: 555–564, 1979

    Article  PubMed  CAS  Google Scholar 

  • Renwick AG. First-pass metabolism within the lumen of the gastrointestinal tract. In George et al. (Eds) Clinical pharmacology and therapeutics: presystemic drug elimination, pp. 3–28, Butterworths, London, 1982

    Google Scholar 

  • Ritschel WA, Brady ME, Tan HSI, Hoffmann KA, Yui IM, et al. Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. European Journal of Clinical Pharmacology 12: 457–461, 1977

    Article  PubMed  CAS  Google Scholar 

  • Roberts MS, Rowland M. A dispersion model of hepatic elimination 1: formulation of the model and bolus considerations. Journal of Pharmacokinetics and Biopharmaceutics 14: 227–260, 1986a

    PubMed  CAS  Google Scholar 

  • Roberts MS, Rowland M. A dispersion model of hepatic elimination 2: steady state considerations — influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. Journal of Pharmacokinetics and Biopharmaceutics 14: 261–288, 1986b

    PubMed  CAS  Google Scholar 

  • Robertson LW, Chandrasekaran A, Reuning RH, Hui J, Rawal BD. Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Applied Environmental Microbiology 51: 1300–1303, 1986

    CAS  Google Scholar 

  • Roden DM, Duff HJ, Altenbern D, Woosley RL. Antiarrhythmic activity of the O-demethyl metabolite of encainide. Journal of Pharmacology and Experimental Therapeutics 221: 552–557, 1982

    PubMed  CAS  Google Scholar 

  • Rogers SM, Back DJ, Orme ML’E. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. British Journal of Clinical Pharmacology 23: 727–734, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Rogers SM, Back DJ, Stevenson PJ, Grimmer SFM, Orme ML’E. Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol. British Journal of Clinical Pharmacology 23: 721–725, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Romiti P, Giuliani L, Pacifici GM. Interindividual variability in the N-sulfation of desipramine in human liver and platelets. British Journal of Clinical Pharmacology 33: 17–23, 1992

    Article  PubMed  CAS  Google Scholar 

  • Routledge PA, George CG. First-pass metabolism by the lung: introduction. In George et al. (Eds) Clinical pharmacology and therapeutics: presystemic drug elimination, pp. 111–116, Butterworths, London, 1982

    Google Scholar 

  • Routledge PA, Stargel WW, Wagner GS, Shand DG. Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Annals of Internal Medicine 93: 701–704, 1980

    PubMed  CAS  Google Scholar 

  • Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1: 123–136, 1973

    PubMed  CAS  Google Scholar 

  • Rowland M. Models to identify sources of pharmacokinetic variability. In Rowland et al. (Eds) Variability in drug therapy: description, estimation, and control, pp. 11–28, Raven Press, New York, 1985

    Google Scholar 

  • Sager G, Hansteen V, Aakesson I, Jacobson S. Effect of heparin on serum binding of propranolol in the acute phase of myocardial infarction. British Journal of Clinical Pharmacology 12: 613–620, 1981

    Article  PubMed  CAS  Google Scholar 

  • Saleh S, Johnston A, Turner P. Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans. British Journal of Clinical Pharmacology 30: 621–624, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clinical Pharmacokinetics 18: 346–364, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sasahara K, Nitanai T, Habara T, Kojima T, Kawahara Y, et al. Dosage form design for improvement of bioavailability of levodopa IV: possible causes of low bioavailability of oral levodopa in dogs. Journal of Pharmaceutical Sciences 70: 730–733, 1981

    Article  PubMed  CAS  Google Scholar 

  • Säwe J, Dahlström B, Rane A. Morphine kinetics in cancer patients. Clinical Pharmacology and Therapeutics 30: 629–635, 1981

    Article  PubMed  Google Scholar 

  • Säwe J, Kager L, Svensson JO, Rane A. Oral morphine in cancer patients: in vivo kinetics and hepatic glucuronidation. British Journal of Clinical Pharmacology 19: 495–501, 1985

    Article  PubMed  Google Scholar 

  • Schaumann W. Pharmacokinetic of isosorbide dinitrate and isosorbide-5-mononitrate. International Journal of Clinical Pharmacology, Therapy and Toxicology 27: 445–453, 1989

    CAS  Google Scholar 

  • Schlepper M. Propafenone, a review of its profile. European Heart Journal 8 (Suppl. A): 27–32, 1987

    PubMed  Google Scholar 

  • Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clinical Pharmacology and Therapeutics 48: 365–374, 1990

    Article  PubMed  CAS  Google Scholar 

  • Schneck DW, Vary JE. Mechanism by which hydralazine alters the bioavailability of propranolol. Clinical Pharmacology and Therapeutics 33: 260, 1983

    Google Scholar 

  • Schneider RE, Bishop H, Hawkins CF. Plasma propranolol concentrations and the erythrocyte sedimentation rate. British Journal of Clinical Pharmacology 8: 43–47, 1979

    Article  PubMed  CAS  Google Scholar 

  • Schneider RE, Bishop H, Kendall MJ, Quarterman CP. Effect of inflammatory disease on plasma concentrations of three β-adrenoceptor blocking agents. International Journal of Clinical Pharmacology, Therapy and Toxicology 19: 158–162, 1981

    CAS  Google Scholar 

  • Schneider RE, Bishop H. β-Blocker plasma concentrations and inflammatory disease: clinical implications. Clinical Pharmacokinetics 7: 281–284, 1982

    Article  PubMed  CAS  Google Scholar 

  • Schroder H, Gustafsson BE. Azo reduction of salicyl-azosulphapyridine in germ-free and conventional rats. Xenobiotica 3: 225–231, 1973

    Article  PubMed  CAS  Google Scholar 

  • Schroder H, Lewkonia RM, Price Evans DA. Metabolism of salicylazosulfapyridine in healthy subjects and patients with ulcerative colitis. Clinical Pharmacology and Therapeutics 14: 802–809, 1973

    PubMed  CAS  Google Scholar 

  • Schulz P, Turner-Tamiyasu K, Smith G, Giacomini KM, Blaschke TF. Amitriptyline disposition in young and elderly normal men. Clinical Pharmacology and Therapeutics 33: 360–366, 1983

    Article  PubMed  CAS  Google Scholar 

  • Schwenk M, Schiemenz C, Del Pino VL, Remmer H. First pass biotransformation of ethinylestradiol in rat small intestine in situ. Naunyn-Schmiedeberg’s Archives of Pharmacology 321: 223–225, 1982

    Article  PubMed  CAS  Google Scholar 

  • Semple HA, Tarn YK, Coutts RT. A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol. Biopharmaceutics and Drug Disposition 11: 61–76, 1990

    Article  CAS  Google Scholar 

  • Semple HA, Koo W, Tam YK, Ngo LY, Coutts RT. Interactions between hydralazine and oral nutrients in humans. Therapeutic Drug Monitoring 13: 304–308, 1991

    Article  PubMed  CAS  Google Scholar 

  • Shand DG, Rangno RE. The disposition of propranolol I: elimination during oral absorption in man. Pharmacology 7: 159–168, 1972

    Article  PubMed  CAS  Google Scholar 

  • Shand DG, Hammill SC, Aanonsen L, Pritchett ELC. Reduced verapamil clearance during long-term oral administration. Clinical Pharmacology and Therapeutics 30: 701–703, 1981

    Article  PubMed  CAS  Google Scholar 

  • Shand DG, Nuckolls EM, Oates JA. Plasma propranolol levels in adults: with observations in four children. Clinical Pharmacology and Therapeutics 11: 112–120, 1970

    PubMed  CAS  Google Scholar 

  • Shand DG. Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs 7: 39–47, 1974

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clinical Pharmacology and Therapeutics 26: 294–305, 1979

    PubMed  CAS  Google Scholar 

  • Sheiner LB, Grasela TH. An introduction to mixed effect modeling: concepts, definitions, and justification. Journal of Pharmacokinetics and Biopharmaceutics 19: 11S–24S, 1991

    Google Scholar 

  • Shepherd AMM, Irvine NA, Ludden TM, Lin MS, McNay JL. Effect of oral dose size on hydralazine kinetics and vasodepressor. Clinical Pharmacology and Therapeutics 36: 595–600, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Shepherd AMM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clinical Pharmacology and Therapeutics 36: 14–18, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Shepherd AMM, Ludden TM, Lin MS, McNay JL. Hydralazine elimination is saturable after oral but not intravenous administration. Clinical Research 30: 258A, 1982

    Google Scholar 

  • Shi YE, He CH, Gu J, Fotherby K. Pharmacokinetics of norethisterone in humans. Contraception 35: 465–475, 1987

    Article  PubMed  CAS  Google Scholar 

  • Shindo H, Fukuda K, Kawai K, Tanaka K. Studies on intestinal absorption of pivampicillin and species differences in the intestinal esterase activity. Journal of Pharmacobio-Dynamics 1: 310–323, 1978

    Article  CAS  Google Scholar 

  • Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785–791, 1987

    Article  PubMed  CAS  Google Scholar 

  • Simpson GM, Cooper TB, Lee JH, Young MA. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology 56: 225–232, 1978

    Article  PubMed  CAS  Google Scholar 

  • Skett P, Young C. The effects of pituitary hormones on hepatic drug metabolism in the rat. Acta Endocrinologica 100: 421–426, 1982

    PubMed  CAS  Google Scholar 

  • Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on verapamil kinetics and dynamics. Clinical Pharmacology and Therapeutics 36: 551–554, 1984

    Article  PubMed  CAS  Google Scholar 

  • Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine: 1987. Clinical Pharmacokinetics 12: 321–366, 1987

    Article  PubMed  CAS  Google Scholar 

  • Soons PA, Vogels BAPM, Roosemalen CM, Schoemaker HC, Uchida E. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clinical Pharmacology and Therapeutics 50: 394–403, 1991

    Article  PubMed  CAS  Google Scholar 

  • Stanaszek WF, Kellerman D, Brogden RN, Romankiewicz JA. Prazosin update: a review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25: 339–384, 1983

    Article  PubMed  CAS  Google Scholar 

  • Stead RJ, Grimmer SFM, Rogers SM, Back DJ, Orme ML’E, et al. Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. Thorax 42: 59–64, 1987

    Article  PubMed  CAS  Google Scholar 

  • Stohs SJ, Grafstrom RC, Burke MD, Moldeus PW, Orrenius SG. The isolation of rat intestinal microsomes, with stable cytochrome P-450 and their metabolism of benzo(a)pyrene. Archives of Biochemistry and Biophysics 1771: 105–116, 1976

    Article  Google Scholar 

  • Storstein L, Larsen A, Midtbø K, Soevareid L. Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. Acta Medica Scandinavica 681 (Suppl.): 25–30, 1984

    PubMed  CAS  Google Scholar 

  • Strong HA, Renwick AG, George CF. The site of reduction of sulphinpyrazone in the rabbit. Xenobiotica 14: 815–826, 1984

    Article  PubMed  CAS  Google Scholar 

  • Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, et al. Effect of food on hepatic blood flow: implications in the ‘food effect’ phenomenon. Clinical Pharmacology and Therapeutics 34: 316–323, 1983

    Article  PubMed  CAS  Google Scholar 

  • Szeto HH, Inturrisi CE, Houde CE, Saal S, Cheigh J, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Annals of Internal Medicine 86: 738–741, 1977

    PubMed  CAS  Google Scholar 

  • Talseth T. Studies on hydralazine III: bioavailability of hydralazine in man. European Journal of Clinical Pharmacology 10: 395–401, 1976b

    Article  PubMed  CAS  Google Scholar 

  • Talseth T. Studies on hydralazine I: serum concentrations of hydralazine in man after a single dose and at steady-state. European Journal of Clinical Pharmacology 10: 183–187, 1976a

    Article  CAS  Google Scholar 

  • Tenero DM, Bottorff MB, Given BD, Kramer WG, Affirme MB, et al. Pharmacokinetics and pharmacodynamics of dilevalol. Clinical Pharmacology and Therapeutics 46: 648–656, 1989

    Article  PubMed  CAS  Google Scholar 

  • Tinguely D, Baumann P, Conti M, Jonzier-Perey M, Schopf J. Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha-1-acid glycoprotein. European Journal of Clinical Pharmacology 27: 661–666, 1985

    Article  PubMed  CAS  Google Scholar 

  • Trenk D, Wagner F, Sachs W, Jahnchen E. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. European Journal of Clinical Pharmacology 37: 313–316, 1989

    Article  PubMed  CAS  Google Scholar 

  • Tschanz C, Steiner JA, Hignite CE, Huffman DH, Azarnoff DL. Systemic availability of lidocaine in patients with liver disease. Clinical Research 25: 609A, 1977

    Google Scholar 

  • Ueda CT, Williamson BJ, Dzindzio BS. Absolute quinidine bioavailability. Clinical Pharmacology and Therapeutics 20: 260–265, 1976

    PubMed  CAS  Google Scholar 

  • Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics 22: 47–65, 1992

    Article  PubMed  CAS  Google Scholar 

  • Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. European Journal of Clinical Pharmacology 27: 91–97, 1984

    PubMed  CAS  Google Scholar 

  • Verbeeck RK, Branch RA, Wilkinson GR. Meperidine disposition in man: influence of urinary pH and route of administration. Clinical Pharmacology and Therapeutics 30: 619–628, 1981

    Article  PubMed  CAS  Google Scholar 

  • Vesell ES, Penno MB. Assessment of methods of identify sources of interindividual pharmacokinetic variations. Clinical Pharmacokinetics 8: 378–409, 1983

    Article  PubMed  CAS  Google Scholar 

  • Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effects of age and cigarette smoking on the disposition of propranolol in man. Clinical Pharmacology and Therapeutics 26: 8–15, 1979a

    PubMed  CAS  Google Scholar 

  • Vestal RE, Kornhauser DM, Hollifield JW, Shand DG. Inhibition of propranolol metabolism by chlorpromazine. Clinical Pharmacology and Therapeutics 25: 19–24, 1979b

    PubMed  CAS  Google Scholar 

  • Villeneuve JP, Thibeault MJ, Ampelas M, Fortunet-Fouin H, LaMarre L, et al. Drug disposition in patients with HBs AG-positive chronic liver disease. Digestive Diseases and Sciences 32: 710–714, 1987

    Article  PubMed  CAS  Google Scholar 

  • Von Daehne W, Gotfredsen E, Roholt K, Tybring L. Pivampicillin: a new orally active ampicillin ester. Antimicrobial Agents and Chemotherapy 10: 431–437, 1970

    Google Scholar 

  • Wagner JG, Rocchini AP, Vasiliades J. Prediction of steady-state verapamil plasma concentrations in children and adults. Clinical Pharmacology and Therapeutics 32: 172–181, 1982

    Article  PubMed  CAS  Google Scholar 

  • Wahlen A, Westerlund D, Wåhlin-Boll E, Melander A. Influence of food intake on the bioavailability of zimelidine and its active metabolite, norzimelidine. Drug Nutrient Interaction 2: 175–181, 1983

    CAS  Google Scholar 

  • Walker KA, Barber HE, Hawksworth GM. Mechanism responsible for altered propranolol disposition in adjuvant-induced arthritis in the rat. Journal of Pharmacology and Experimental Therapeutics 14: 482–486, 1986

    CAS  Google Scholar 

  • Walle T, Walle KU, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clinical Pharmacology and Therapeutics 46: 257–263, 1989

    Article  PubMed  CAS  Google Scholar 

  • Walle T, Fagan TC, Walle UK, Oexmann MJ, Conradi EC, et al. Food-induced increase in propranolol bioavailability-relationship to protein and effects on metabolites. Clinical Pharmacology and Therapeutics 30: 790–795, 1981

    Article  PubMed  CAS  Google Scholar 

  • Wang T, Roden DM, Wolfenden HT, Woosley RL, Wilkinson GR, et al. Pharmacokinetics of encainide and its metabolites in man. Clinical Pharmacology and Therapeutics 31: 278, 1982

    Google Scholar 

  • Watson RGP, Bastain W, Larkin KA, Hayes JR, McAinsh JA. A comparative pharmacokinetic study of conventional propranolol and a long acting preparation of propranolol in patients with cirrhosis and normal controls. British Journal of Clinical Pharmacology 24: 527–535, 1987

    Article  PubMed  CAS  Google Scholar 

  • Weber WW. Acetylation of drugs. In Fishman (Ed.) Metabolic conjugation and metabolic hydrolysis, Vol. 3, pp. 249–296, Academic Press, Inc., New York, 1973

    Google Scholar 

  • Weiss M. Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction. Clinical Pharmacokinetics 18: 419–422, 1990

    Article  PubMed  CAS  Google Scholar 

  • Wilson K. Sex-related differences in drug disposition in man. Clinical Pharmacokinetics 9: 189–202, 1984

    Article  PubMed  CAS  Google Scholar 

  • Winkle RA, Peters F, Kates RE, Tucker C, Harrison DC. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Circulation 64: 290–296, 1981

    Article  PubMed  CAS  Google Scholar 

  • Winkler K, Bass L, Keiding S, Tygstrup N. The effect of hepatic perfusion on the assessment of kinetic constants. In Lundqvist & Tygstrup (Eds) Regulation of hepatic metabolism, pp. 797–807, Munksgaard, Copenhagen, 1974

    Google Scholar 

  • Winkler K, Bass L, Keiding S, Tygstrup N. The physiologic basis for clearance measurements in hepatology. Scandinavian Journal of Gastroenterology 14: 439–448, 1979

    PubMed  CAS  Google Scholar 

  • Winkler K, Keiding S, Tygstrup N. Clearance as a quantitative measure of liver function. In Paumgartner & Preisig (Eds) The liver: quantitative aspects of structure and function, pp. 144–155, Karger, Basel, 1973

    Google Scholar 

  • Wolf CR, Szutowski MM, Ball LM, Philpot RM. The rabbit pulmonary mono-oxygenase system: characteristics and activities of two forms of pulmonary cytochrome P-450. Chemio-Biological Interactions 21: 29–43, 1978

    Article  CAS  Google Scholar 

  • Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clinical Pharmacokinetics 3: 478–487, 1978

    Article  PubMed  CAS  Google Scholar 

  • Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clinical Pharmacokinetics 20: 350–373, 1991

    Article  PubMed  CAS  Google Scholar 

  • Wood AJJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, et al. Propranolol disposition in renal failure. British Journal of Clinical Pharmacology 10: 561–566, 1980

    Article  PubMed  CAS  Google Scholar 

  • Woodcock BG, Kraemer N, Rietbrock N. Effect of a high protein meal on the bioavailability of verapamil. British Journal of Clinical Pharmacology 21: 337–338, 1986

    Article  PubMed  CAS  Google Scholar 

  • Woodhouse K, Wynne HA. Age-related changes in hepatic function: implications for drug therapy. Drugs & Aging 2: 243–255, 1992

    Article  CAS  Google Scholar 

  • Woosley RL, Roden DM, Duff HJ, Carey EL, Wood AJJ, et al. Co-inheritance of deficient oxidative metabolism of encainide and debrisoquine. Clinical Research 29: 501 A, 1981

    Google Scholar 

  • Worland PJ, Ilett KF. Intestinal contribution to the presystemic elimination of beta-phenylethylamine in the rat. Journal of Pharmacy and Pharmacology 35: 636–640, 1983

    Article  PubMed  CAS  Google Scholar 

  • Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9: 297–301, 1989

    Article  PubMed  CAS  Google Scholar 

  • Yasuhara H, Kiuchi Y, Oguchi K, Davies DS, Dollery CT. The effects of amiflavine, a reversible MAO-inhibitor, on the first-pass metabolism of tyramine in dog intestine. Japanese Journal of Pharmacology 41: 505–510, 1986

    Article  PubMed  CAS  Google Scholar 

  • Yu VC, De Lamirande E, Horning MG, Pang KS. Dose-dependent kinetics of quinidine in the perfused rat liver preparation: kinetics of formation of active metabolites. Drug Metabolism and Disposition 10: 568–572, 1982

    PubMed  CAS  Google Scholar 

  • Zile MH, Inhorn RC, Deluca HF. Metabolism in vitro of alltrans-retinoic acid: biosynthesis of 13-cis-retinoic acid and alltrans-and 13-cis-retinoyl glucuronides in the intestinal mucosa of the rat. Journal of Biological Chemistry 257: 3544–3550, 1982

    PubMed  CAS  Google Scholar 

  • Zimm S, Collins JM, Riccardi R, O’Neill D, Narang PK, et al. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? New England Journal of Medicine 308: 1005–1009, 1983

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    Yun K. Tam

Authors
  1. Yun K. Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tam, Y.K. Individual Variation in First-Pass Metabolism. Clin. Pharmacokinet. 25, 300–328 (1993). https://doi.org/10.2165/00003088-199325040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325040-00005

Keywords

Search

Navigation